Neurology News | Medical XPRT

Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene ...

Mar. 30, 2021

By Dicerna Pharmaceuticals, Inc.

Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine

Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...

Mar. 30, 2021

By Aspect Biosystems Ltd.

bit.bio CEO Dr Mark Kotter speaking about challenging biology at the TEDxCambridgeUniversity ‘Untangling networks’ event

On Saturday 20 March 2021, bit.bio CEO and founder Mark Kotter was a speaker at the TEDxCambridgeUniversity ‘Untangling networks’ event. Dr Kotter was speaking about his work as a neurosurgeon, stem cell biologist and an entrepreneur. Many of the conditions he faces as a doctor, whether they are cancers, genetic or degenerative conditions, need more than a scalpel and screws or ...

Mar. 26, 2021

By bit.bio

BrainScope Launches Next-Gen Medical Device: First and only FDA-cleared system for true point-of-care assessment of both concussion and brain bleeds now includes Concussion Index

BrainScope today announced the availability of its third groundbreaking FDA-cleared algorithm on the BrainScope device. The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at baseline, point of injury, and through recovery. The Concussion Index adds to the suite of FDA cleared algorithms already available on the ...

Mar. 23, 2021

By BrainScope

Inspire Medical Systems, Inc. Announces FDA Approval of Two-Incision Implant Procedure

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced receipt of U.S. Food and Drug Administration (“FDA”) approval for an improved surgical implant procedure that eliminates one incision ...

Mar. 15, 2021

By Inspire Medical Systems, Inc.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2020

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the fourth quarter and full-year 2020. Recent Highlights Senhance Surgical System received expanded 510(k) clearance for general ...

Mar. 11, 2021

By Asensus Surgical US, Inc.

Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. New real-world data will be presented evaluating SOLIRIS® (eculizumab) for the treatment of generalized myasthenia gravis (gMG) in the United ...

Mar. 4, 2021

By Alexion Pharmaceuticals, Inc.

Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA. "We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital ...

Mar. 2, 2021

By Theranica Bio-Electronics Ltd.

Forest Devices Announces Positive Study Results For Their Stroke Detection Technology

Medical technology pioneer Forest Devices, Inc. (FDI) today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive (LVO) strokes in emergency departments in the American Heart Association Journal, STROKE. LVOs are the type of ischemic stroke that require an interventional thrombectomy, only ...

Feb. 23, 2021

By Forest Devices

JAMA Highlights Success of BrainScope`s EEG-based Concussion Index As Reliable Indicator of Concussion

JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion Index, to indicate the likelihood and severity of concussive brain injury and to aid in evaluating an athlete's readiness to return to play. "What ...

Feb. 16, 2021

By BrainScope

Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL Mini Sinus Implant

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received ...

Feb. 11, 2021

By Intersect ENT, Inc.

UPM Biomedicals fights cancer with GrowDex®

Cancer is the second leading cause of death globally, and unfortunately a growing global burden. With an estimated 18 million cancer cases yearly around the world, cancer is one of the most significant public health challenges of the 21st century. UPM Biomedicals joins the fight against cancer with a wood-based hydrogel, GrowDex®. The hydrogel made of birch and water supports cell growth by ...

Feb. 4, 2021

By UPM

FDA Approves Theranica`s Nerivio® for Acute Treatment of Migraine in Adolescents

Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. The use of the device in the ...

Jan. 25, 2021

By Theranica Bio-Electronics Ltd.

Nanox Announces Three Key Senior Level Hires to Support Long-Term Growth Objectives

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today three senior level additions to the leadership team to further support the Company’s long-term growth objectives. The Company announced that Jim Dara has joined as Chief Operating Officer, Ofir Koren as Chief Technology Officer and Tamar ...

Jan. 20, 2021

By Nano-X Imaging Ltd.

Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro`s HF10® Therapy

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) randomized ...

Jan. 19, 2021

By Nevro Corp.

Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HF10® therapy for patients with chronic pain. Results will be presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January ...

Jan. 14, 2021

By Nevro Corp.

Carmat outlines commercial and development plan for its total artificial heart

Addressable market in the bridge-to-transplant indication of more than 2,000 patients a year in Europe Company prepares for commercial launch in Q2 2021, with initial focus on Germany and France Robust clinical plan to support adoption and sales development Virtual conference with Stéphane Piat today at 5 pm CET CARMAT (FR0010907956, ALCAR), the designer and developer of the ...

Jan. 6, 2021

By Carmat

Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases

LONDON – Friday 18 December 2020 – Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead ...

Dec. 18, 2020

By Gyroscope Therapeutics Limited

AstraZeneca to Acquire Alexion, Accelerating the Company`s Strategic and Financial Development

AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on ...

Dec. 12, 2020

By Alexion Pharmaceuticals, Inc.

Digital Healthcare: This Software Marketplace Lets Hospitals Test-Drive AI-Powered Apps

The last time you bought a new car, you probably didn’t just write a check. You took it for a spin to see how it handles. GE Healthcare will soon offer a similar service to hospitals interested in buying its latest software powered by artificial intelligence (AI). “This is a big deal for the healthcare industry,” says Ken Denison, vice president of digital platform and product ...

Dec. 3, 2020

By GE Renewable Energy